05271nam 2201585z- 450 991105303200332120230911(CKB)5690000000228617(oapen)doab113964(EXLCZ)99569000000022861720230920c2023uuuu -u- -engurmn|---annantxtrdacontentcrdamediacrrdacarrierUpdates on Molecular Targeted Therapies for CNS TumorsMDPI - Multidisciplinary Digital Publishing Institute20231 online resource (368 p.)3-0365-8529-X The challenges in identifying effective therapies for CNS tumors continue to be daunting. Potentially effective targeted therapies must be able to penetrate the blood-brain barrier to reach the tumor and, in sufficient concentrations, to result in meaningful treatment responses. Moreover, molecular targets must be key drivers in the growth and progression of CNS tumors. Numerous potentially efficacious therapies have failed in randomized clinical trials due to other factors, including subclonal genetic intratumoral heterogeneity (particularly within malignant gliomas), epigenetic heterogeneity, and failure to target important factors involved in the tumor microenvironment. Developing effective targeted therapies requires a thorough fundamental understanding of the genetic and epigenetic factors driving tumor progression, the interactions between CNS tumor cells and the tumor microenvironment, and the key mechanisms of tumor treatment resistance. In this Special Issue, experts in the field of CNS tumors will highlight the most promising molecular targets in the development of treatments for patients with CNS tumors.Medicine and NursingbicsscOncologybicsscA172A2AAR antagonistadenosineadenosine receptorsantigen processing and presentationantioxidantapoptosisATRXbevacizumabbiomarkerblood-brain barrierbrain metastasisbrain tumorcancer metabolismcell cycle arrestcentral nervous systemchemotherapyCNS diseaseCNS lymphomaCpG islanddiffuse midline gliomasDNMTEGFRependymomaEPHB2epidermal growth factor receptorERK/MAPK pathwayFGFR3G-CIMPGBMgermline mutationglioblastomaglioblastoma molecular classificationgliomaGroup AGroup BH3K27Mhistone acetylationIDH-mutant gliomaimmune evasionimmune scoreimmunotherapyintraparenchymal metastasesintrathecalisotope labelingKIF11leptomeningeallow grade gliomalow-grade gliomaLPSlung cancerlung carcinomalung malignancymass spectrometrymeningitisMETmetastatic diseaseMetforminmethotrexatemethylationmethylomicsmethyltransferasesMGMTmolecular targetsmolecular therapymonoclonal antibodiesMYCNmyxopapillaryn/aneoantigenneoplasticneurofibromatosisNF1novel therapeuticsnovel therapiespatient avatarsPCNSLPDGFRApediatric brain tumorPFAPFBPI3K/PTEN pathwayplexiform neurofibromapotential therapy developmentpreclinical modelsprogressionprogression-free survivalradiotherapyreceptor tyrosine kinaseRELAstereotactic radiosurgerysubependymomaT cellsT lymphocytestargeted therapytemozolomidetumor microenvironmenttumor mutation burdentumor suppressortyrosine kinase inhibitorsU87MGvestibular schwannomaWarburg effectwhole-brain radiation therapyYAP1ZFTAMedicine and NursingOncologyBOOK9911053032003321Updates on Molecular Targeted Therapies for CNS Tumors4526180UNINA